Patents Examined by Nissa M Westerberg
-
Patent number: 11944097Abstract: The present disclosure generally describes an antimicrobial composition comprising: a water solution comprising a chlorite salt and/or chlorine dioxide having a concentration ranging from about 2,000 parts per million to about 8,000 parts per million, and at least one quaternary ammonium salt having a concentration ranging from about 5,000 parts per million to about 10,000 parts per million. The present compositions are advantageously effective against a variety of bacteria, viruses, molds, and fungi, and may be used in a variety applications. Such applications include, without limitation, healthcare setting and equipment disinfection, food surface disinfection, agricultural disinfection, and personal hand care disinfection.Type: GrantFiled: June 5, 2020Date of Patent: April 2, 2024Assignee: Aseptic Health, LLCInventors: Michael Politopoulos, Autumn N. Ryan, Gustave J. Scannapieco
-
Patent number: 11931431Abstract: The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to which a radioactive metal-coupled chelator is structurally coupled and to which an aryl group that can additionally bind to PSMA protein is coupled. Coupling between the glutamine-urea-lysine compound and the chelator includes a polar spacer so as to serve the role of reducing in vivo nonspecific coupling and exhibit an effect of being rapidly removed from vital organs, but not from prostate cancer. These characteristics lower the radiation exposure, which is caused by a therapeutic radioisotope-coupled compound, to normal tissue and organs, and thus reduce side effects. In addition, a compound that contains a phenyl group having a coupling force with albumin has an increased residence time in the blood, thereby becoming more accumulated in prostate cancer.Type: GrantFiled: March 29, 2019Date of Patent: March 19, 2024Assignee: FUTURECHEM CO., LTDInventors: Dae Yoon Chi, Byoung Se Lee, So Young Chu, Hyeon Jin Jeong, Min Hwan Kim, Kyo Chul Lee, Yong Jin Lee
-
Patent number: 11896646Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.Type: GrantFiled: October 14, 2022Date of Patent: February 13, 2024Assignee: Nammi Therapeutics, Inc.Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
-
Patent number: 11890384Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.Type: GrantFiled: February 13, 2017Date of Patent: February 6, 2024Assignee: Tricol Biomedical, Inc.Inventors: Brian Clare, Radim Dvo{hacek over (r)}ák, Simon McCarthy, Jiri Machát
-
Patent number: 11877998Abstract: One or more techniques and/or systems are disclosed for a method of administering a composition of an orally administered agent devised to provide desirable nutrients and other supplements to the body, which may help mitigate degradation of the skin, and may help promote the health of the skin, and/or treatment of skin conditions. The composition can comprise ingredients of a selected type, amount, and source, which, in this particular arrangement, may promote healthy skin and improve skin condition in a person. A composition that promotes healthy skin can comprise vitamin A; vitamin C; vitamin E; vitamin B6; zinc; rose hip extract; copper; and vitamin B3.Type: GrantFiled: September 9, 2019Date of Patent: January 23, 2024Assignee: H &H Science, LLCInventors: Helen M. Torok, Heather L Funk
-
Patent number: 11786477Abstract: Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.Type: GrantFiled: December 3, 2018Date of Patent: October 17, 2023Assignee: North Carolina State UniversityInventors: Ismaeel Muhamed, Ashley C. Brown, Frances S. Ligler
-
Patent number: 11779634Abstract: A method of treating a fungal infection in a subject includes topically administering to the subject a therapeutically effective amount of a fungal iron acquisition inhibitor to treat fungal infection in the subject.Type: GrantFiled: January 25, 2022Date of Patent: October 10, 2023Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Eric Pearlman, Sixto M. Leal, Jr.
-
Patent number: 11766428Abstract: Provided is a topical pharmaceutical gel composition of an amlodipine salt and methods for its use in the treatment of anorectal disease.Type: GrantFiled: July 16, 2021Date of Patent: September 26, 2023Assignee: TAVANTA THERAPEUTICS HUNGARY INCORPORATEDInventors: László Ritter, László Hornok, Péter Mátyus, Romána Zelkó, Andrea Ujhelyi, Richárd Balázs Kárpáti, Tamás Solymosi, Hristos Glavinas
-
Patent number: 11744874Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.Type: GrantFiled: December 21, 2020Date of Patent: September 5, 2023Assignee: Nammi Therapeutics, Inc.Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
-
Patent number: 11737977Abstract: A cerasome delivery system for targeting activated cd44 molecule, a preparation method and use thereof: a surface of a cerasome is partially modified by a targeting ligand, the targeting ligand being a ligand which may specifically bind to an activated cd44 molecule. The cerasome delivery system may be used for the diagnosis, prevention and treatment of vulnerable plaque or diseases associated with vulnerable plaque.Type: GrantFiled: April 12, 2018Date of Patent: August 29, 2023Assignee: Beijing Inno Medicine Co., Ltd.Inventors: Qian Ma, Jiefang Sun
-
Patent number: 11712484Abstract: A method for generating vapour bubbles in an object comprises introducing a composition into the object, the composition comprising carbon-based nano- or microparticles that can couple with a photon wave of electromagnetic radiation. The method also comprises irradiating said object using electromagnetic radiation. The irradiation thereby is adapted for using a set of carbon-based nano- or microparticles for subsequently forming first vapour bubbles and at least second vapour bubbles using the same carbon-based nano- or microparticles.Type: GrantFiled: June 29, 2016Date of Patent: August 1, 2023Assignees: UNIVERSITEIT GENT, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS, UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE 1Inventors: Kevin Braeckmans, Stefaan De Smedt, Joseph Demeester, Sangram Keshari Samal, Ranhua Xiong, Sabine Szunerits, Rabah Boukherroub
-
Patent number: 11679141Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.Type: GrantFiled: April 16, 2021Date of Patent: June 20, 2023Assignee: Nammi Therapeutics, Inc.Inventors: David Stover, Dhruba Bharali, Bruce A Hay, Tahmineh Safaie
-
Patent number: 11679112Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.Type: GrantFiled: August 30, 2021Date of Patent: June 20, 2023Assignee: BIOMED VALLEY DISCOVERIES, INC.Inventors: Saurabh Saha, Dean Welsch, Gary DeCrescenzo, Jeffrey James Roix
-
Patent number: 11654186Abstract: The present disclosure relates to the synergistic combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, a cofactor of the enzyme, and a glucan. The present disclosure also relates to the synergistic combination of sulforaphane or a derivative thereof and a glucan. The present disclosure also relates to the synergistic combination of a broccoli extract or powder and a glucan. The glucan may be a ?-glucan. The glucan may be provided in a mushroom extract or powder selected from one or more of a maitake, a shiitake, or a reishi mushroom. Compositions and methods relating to these combinations are described.Type: GrantFiled: December 3, 2019Date of Patent: May 23, 2023Assignee: Nutramax Laboratories, Inc.Inventors: Brian Cornblatt, Grace Cornblatt, Anton Bzhelyansky, Robert Henderson
-
Patent number: 11628228Abstract: A 99mTc-labeled isonitrile-containing glucose derivative having the general formula [99mTc-(CNDG)6]+, preparation method and use thereof is disclosed herein. The derivative is centered on 99mTc+, and the carbon atom of the isonitrile in CNDG coordinates with 99mTc(I) to form a hexacoordinated complex [99mTc-(CNDG)6]+. The [99mTc-(CNDG)6]+ derivative was obtained by the synthesis of the ligand CNDG and the preparation of the lyophilized CNDG kit. The derivative of this disclosure has good stability, simple preparation, high uptake and good retention at a tumor site, and high tumor/non-target ratio, and it is a novel 99mTc-labeled isonitrile-containing glucose derivative with excellent performance for tumor imaging. The derivative of this disclosure is advantageous for popularization and application.Type: GrantFiled: January 24, 2018Date of Patent: April 18, 2023Assignee: Beijing Shihong Pharmaceutical Research CenterInventors: Junbo Zhang, Xuran Zhang, Qianqian Gan, Xin Shao, Xuebin Wang, Zhigang Tang, Jie Lu, Zhanbin Zhang
-
Patent number: 11590241Abstract: Provided herein are nanoparticle conjugated synthetic opioid prodrugs that target the peripheral mu opioid receptor (MOR). The prodrugs exhibit long-lived bioavailability, do not compromise the analgesic effects of opioids administered for pain relief (and in some cases can be used for pain relief), and do not induce opioid withdrawal symptoms, when their use is discontinued. Certain of the prodrugs are especially useful for the prevention and/or treatment of unwanted opioid-induced side effects such as opioid-induced constipation (OIC).Type: GrantFiled: February 17, 2017Date of Patent: February 28, 2023Assignee: Virginia Commonwealth UniversityInventors: Yan Zhang, Hu Yang, Dana Selley, William Dewey, Hamid Akbarali
-
Patent number: 11564995Abstract: Described herein is a nanoparticle system including a multivalent nanoparticle core having a plurality of ?-hairpin peptides conjugated thereto. Also included are pharmaceutical compositions and methods of making the nanoparticle system. Further included are immunotherapy methods including administering the nanoparticle system to a subject in need thereof, such as a human cancer patient.Type: GrantFiled: October 29, 2020Date of Patent: January 31, 2023Assignee: WISCONSIN ALUMNI RESEARCH FOUNDATIONInventors: Seungpyo Hong, Woo-jin Jeong
-
Patent number: 11446238Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.Type: GrantFiled: September 27, 2016Date of Patent: September 20, 2022Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra Navath, Anupa Menjoge
-
Patent number: 11439581Abstract: The present invention provides an epilatory composition comprising an admixture of a hydrocarbon resin material and a mineral oil in weight ratio of 1.3:1 to 2.8:1, and, a polyethylene in the form of a homopolymer. An advantage of the compositions of the present invention is that they can be heated to the correct temperature of use, and/or to the correct viscosity, in an advantageous time.Type: GrantFiled: October 21, 2020Date of Patent: September 13, 2022Assignee: Reckitt Benckiser Health LimitedInventors: Alice Heather Pope, Terry Alan Cass, Victoria Mary Morris-Curtis
-
Patent number: 11439580Abstract: The present invention provides an epilatory composition comprising an admixture of a hydrocarbon resin material and a mineral oil in weight ratio of 1.3:1 to 2.8:1, particulate silica, and, a polyethylene in the form of a homopolymer. An advantage of the compositions of the present invention is that they are able to provide good ‘grip’ to the hair to be removed and so provide for effective hair removal properties.Type: GrantFiled: October 21, 2020Date of Patent: September 13, 2022Assignee: Reckitt Benckiser Health LimitedInventors: Terry Alan Cass, Victoria Mary Morris-Curtis, Alice Heather Pope